|
US3647858A
(en)
|
1970-05-01 |
1972-03-07 |
Merck & Co Inc |
Process for preparing 1-benzylidene-3-indenyl acetic acids
|
|
US3654349A
(en)
|
1970-05-01 |
1972-04-04 |
Merck & Co Inc |
Substituted indenyl acetic acids
|
|
US4413141A
(en)
|
1977-07-11 |
1983-11-01 |
Merrell Toraude Et Compagnie |
2-(Difluoromethyl)-2,5-diaminopentanoic acid
|
|
US4330559A
(en)
|
1977-07-11 |
1982-05-18 |
Merrell-Toraude Et Cie |
Method of treating benign prostatic hypertrophy
|
|
US4309442A
(en)
|
1977-07-11 |
1982-01-05 |
Merrell Toraude Et Compagnie |
Method for controlling fertility in mammals
|
|
US4499072A
(en)
|
1982-11-29 |
1985-02-12 |
Merrell Dow Pharmaceuticals Inc. |
Process for treating diseases with ODC inhibitors
|
|
US4859452A
(en)
|
1986-01-17 |
1989-08-22 |
Board Of Regents, The University Of Texas System |
Methods for the reduction of difluoromethylornithine associated toxicity
|
|
US4925835A
(en)
|
1986-05-01 |
1990-05-15 |
Sloan-Kettering Institute For Cancer Research |
Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
|
|
US5002879A
(en)
|
1986-05-06 |
1991-03-26 |
Merrell Dow Pharmaceuticals |
Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5846945A
(en)
|
1993-02-16 |
1998-12-08 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
FR2706255B1
(fr)
|
1993-06-17 |
1995-10-27 |
Univ Rennes |
Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
|
|
AU7326594A
(en)
|
1993-07-09 |
1995-02-06 |
Synergen, Inc. |
Recombinant ctla4 polypeptides and methods for making the same
|
|
US5456908A
(en)
|
1994-03-01 |
1995-10-10 |
The University Of Kentucky Research Foundation |
Polyamine-polyamine and polyamine-protein transport inhibitor conjugates and their use as pharmaceuticals and in research relating to polyamine transport
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
|
US5843929A
(en)
|
1996-03-22 |
1998-12-01 |
Mayo Foundation For Medical Education And Research |
Chemoprevention of metachronous adenomatous colorectal polyps
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
US6083496A
(en)
|
1996-10-22 |
2000-07-04 |
Universite Laval |
Polyamine transport inhibitors
|
|
AU5200098A
(en)
|
1996-11-01 |
1998-05-29 |
Ilex Oncology, Inc. |
Sustained release formulation containing dfmo
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
CA2325080A1
(en)
|
1998-03-28 |
1999-10-07 |
The Regents Of The University Of California |
Dfmo and sulindac combination in cancer chemoprevention
|
|
CA2304557C
(en)
|
1998-04-21 |
2008-12-30 |
Universite Laval |
Polyamine transport inhibitors
|
|
US7700568B2
(en)
|
1998-06-30 |
2010-04-20 |
Sloan-Kettering Institute For Cancer Research |
Uses of DNA-PK
|
|
DK1141028T3
(da)
|
1998-12-23 |
2010-05-25 |
Pfizer |
Humane monoklonale antistoffer til CTLA-4
|
|
US6753422B2
(en)
|
1999-03-01 |
2004-06-22 |
O'brien Thomas G. |
Odc allelic analysis method for assessing carcinogenic susceptibility
|
|
CA2373931A1
(en)
|
1999-05-17 |
2000-11-23 |
Richard Love |
Dfmo and celecoxib in combination for cancer chemoprevention and therapy
|
|
US6428809B1
(en)
|
1999-08-18 |
2002-08-06 |
Microdose Technologies, Inc. |
Metering and packaging of controlled release medication
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
|
WO2001068076A2
(en)
|
2000-03-07 |
2001-09-20 |
Ilex Oncology, Inc. |
D-enantiomer of dfmo and methods of use thereof for treating cancer
|
|
US6602910B2
(en)
|
2000-03-07 |
2003-08-05 |
Ilex Oncology, Inc. |
D-enantiomer of DFMO and methods of use therefor
|
|
AU2001285232A1
(en)
|
2000-08-24 |
2002-03-04 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Alpha-difluoromethylornithine (dfmo) use in the human prostate
|
|
US7030126B2
(en)
|
2001-11-16 |
2006-04-18 |
Als Therapy Development Foundation, Inc. |
Use of polyamine analogs for amyotrophic lateral sclerosis
|
|
MXPA05005781A
(es)
|
2002-11-29 |
2005-12-12 |
Forest Laboratories |
Combinacion de ibuprofeno y oxicodona para alivio de dolor agudo.
|
|
US20100009929A1
(en)
|
2004-03-29 |
2010-01-14 |
Cheng Jin Q |
Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
WO2007075673A1
(en)
|
2005-12-20 |
2007-07-05 |
University Of Hawaii |
Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
|
|
ES2380747T3
(es)
|
2006-07-18 |
2012-05-18 |
Horizon Pharma Usa, Inc. |
Métodos y medicamentos para administración de ibuprofeno
|
|
TWI577695B
(zh)
*
|
2006-12-19 |
2017-04-11 |
建南德克公司 |
用於輔助及先導性輔助療法之血管內皮生長因子（ｖｅｇｆ）-特異性拮抗劑及早期腫瘤之治療
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
SG183010A1
(en)
|
2007-08-01 |
2012-08-30 |
Sigma Tau Ind Farmaceuti |
Treatment of pediatric tumors
|
|
US8283331B2
(en)
|
2007-10-09 |
2012-10-09 |
Children's Medical Center Corporation |
Methods to regulate miRNA processing by targeting Lin-28
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
US8278065B2
(en)
|
2008-06-30 |
2012-10-02 |
Morphotek, Inc. |
Polynucleotides encoding anti-GD2 antibodies
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
US8815872B2
(en)
|
2008-09-08 |
2014-08-26 |
Merck Patent Gmbh |
Macrocyclics pyrimidines as aurora kinase inhibitors
|
|
US20100120727A1
(en)
*
|
2008-11-12 |
2010-05-13 |
Kyphia Pharmaceuticals, Inc. |
Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
|
|
AU2009333510A1
(en)
|
2008-12-08 |
2011-06-30 |
The Procter & Gamble Company |
Personal care composition in the form of an article having a hydrophobic surface-resident coating
|
|
DK2430452T3
(da)
|
2009-05-14 |
2014-10-06 |
Univ Arizona State |
Carcinom-diagnose og behandlinger, baseret på odc1-genotype
|
|
CN102802729A
(zh)
|
2009-05-20 |
2012-11-28 |
兰贝克赛实验室有限公司 |
异维a酸的液体剂型
|
|
US9212131B2
(en)
|
2009-06-19 |
2015-12-15 |
University Of Central Florida Research Foundation, Inc. |
Polyamine transport inhibitors as novel therapeutics
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
PL3053932T3
(pl)
|
2010-02-19 |
2021-03-08 |
Xencor, Inc. |
Nowe immunoadhezyny CTLA4-IG
|
|
US20110256161A1
(en)
|
2010-04-19 |
2011-10-20 |
Aminex Therapeutics Inc. |
Methods for enhancing immune response
|
|
CA2800557A1
(en)
|
2010-04-29 |
2011-11-03 |
Medical Prognosis Institute A/S |
Methods and devices for predicting treatment efficacy
|
|
CA2799431A1
(en)
|
2010-05-14 |
2011-11-17 |
Cancer Prevention Pharmaceuticals, Inc. |
Cancer prevention and treatment methods based on dietary polyamine content
|
|
DK3323830T3
(da)
|
2010-06-19 |
2023-09-25 |
Memorial Sloan Kettering Cancer Center |
Anti-gd2 antibodies
|
|
EP3467101A3
(en)
|
2010-09-08 |
2019-06-19 |
Baylor College of Medicine |
Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
|
|
WO2012135641A2
(en)
|
2011-03-30 |
2012-10-04 |
H. Lee Moffitt Cancer Center And Research Institute |
Aurora kinase inhibitors and methods of making and using thereof
|
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
CA2889711A1
(en)
|
2012-10-29 |
2014-05-08 |
Arizona Board Of Regents On Behalf Of University Of Arizona |
Predictive markers for polyamine inhibitor cancer therapies
|
|
GB2513299A
(en)
|
2013-03-12 |
2014-10-29 |
Cellact Pharma Gmbh Biomedizinzentrum |
Compounds for targeting cancer stem cells
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
CN105705165B
(zh)
|
2013-03-15 |
2020-04-24 |
纪念斯隆-凯特琳癌症中心 |
高亲和力抗gd2抗体
|
|
CA2917858A1
(en)
|
2013-08-02 |
2015-02-05 |
Aduro Biotech Holdings, Europe B.V. |
Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
WO2015195120A1
(en)
|
2014-06-18 |
2015-12-23 |
Arizona Board Of Regents On Behalf Of University Of Arizona |
Carcinoma diagnosis and treatment based on odc1 genotype
|
|
WO2016130918A1
(en)
|
2015-02-12 |
2016-08-18 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Methods for treating neuroblastoma
|
|
KR20260033630A
(ko)
*
|
2015-10-30 |
2026-03-10 |
캔서 프리벤션 파마수티컬스, 인코포레이티드 |
에플로르니틴 및 설린닥, 고정된 용량 조합 제제
|
|
WO2017075576A1
(en)
*
|
2015-10-30 |
2017-05-04 |
Cancer Prevention Pharmaceuticals, Inc. |
Eflornithine and sulindac, fixed dose combination formulation
|
|
JP2022532766A
(ja)
*
|
2019-05-17 |
2022-07-19 |
キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド |
家族性腺腫性ポリポーシスを処置するための方法
|